{"id":"interferon-beta-1a-fbs-free-hsa-free","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Flu-like symptoms (fever, chills, myalgia)"},{"rate":"30-50","effect":"Injection site reactions"},{"rate":"20-40","effect":"Headache"},{"rate":"20-35","effect":"Fatigue"},{"rate":"10-20","effect":"Depression/mood changes"},{"rate":"10-15","effect":"Elevated liver enzymes"},{"rate":"5-10","effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL1201562","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon-beta-1a is a recombinant cytokine that binds to type I interferon receptors (IFNAR1/IFNAR2) on the surface of immune and other cells, triggering intracellular signaling cascades that increase expression of antiviral proteins, enhance natural killer cell activity, and modulate T-cell responses. The FBS-free/HSA-free formulation removes animal-derived serum components and human serum albumin, improving manufacturing consistency and reducing potential immunogenic contaminants while maintaining the same biological activity as standard interferon-beta-1a.","oneSentence":"Interferon-beta-1a activates interferon-alpha/beta receptors on immune cells to enhance antiviral and immunomodulatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:25.381Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis (relapsing-remitting form)"},{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT00110396","phase":"PHASE3","title":"Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2005-01","conditions":"Multiple Sclerosis","enrollment":260}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Interferon-beta-1a FBS-free/HSA-free","genericName":"Interferon-beta-1a FBS-free/HSA-free","companyName":"EMD Serono","companyId":"emd-serono","modality":"Biologic","firstApprovalDate":"","aiSummary":"Interferon-beta-1a activates interferon-alpha/beta receptors on immune cells to enhance antiviral and immunomodulatory responses. Used for Multiple sclerosis (relapsing-remitting form), Relapsing forms of multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}